CLEC12A single-chain variable fragment

CLEC12A single-chain variable fragment is a **protein antibody fragment** that serves as the CLEC12A-targeting binding domain within an investigational trispecific killer engager immunotherapy for myeloid malignancies. In the reported construct developed by researchers at the University of Minnesota with GT Biopharma, the CLEC12A scFv is paired with an anti-CD16 NK-cell engaging domain and an interleukin-15 cytokine domain to redirect and expand natural killer cell activity against **CLEC12A-expressing acute myeloid leukemia and myelodysplastic syndrome cells**, including leukemic stem cells while sparing normal hematopoietic stem cells. As an isolated entity, this scFv is not described as a standalone marketed drug; rather, it is a targeting module within a larger recombinant biologic engager platform that has supported preclinical activity and phase 1 clinical development of the full TriKE molecule.

Other names

CLEC12A scFvCLEC-12A scFvCLEC 12A scFvsingle-chain variable fragment against human CLEC12Aanti-CLEC12A single-chain variable fragmentanti-CLEC-12A single-chain variable fragmentanti-CLEC 12A single-chain variable fragment